Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2009-09-10
2011-12-13
Rawlings, Stephen (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S139100, C424S143100, C530S350000, C530S387100, C530S387300, C530S388220
Reexamination Certificate
active
08075887
ABSTRACT:
The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
REFERENCES:
patent: 5599905 (1997-02-01), Mosley et al.
patent: 5714146 (1998-02-01), Lewis
patent: 5717072 (1998-02-01), Mosley
patent: 5856296 (1999-01-01), Mosley et al.
patent: 5985280 (1999-11-01), Ritter
patent: 6156877 (2000-12-01), Ritter et al.
patent: 6391581 (2002-05-01), Mosley et al.
patent: 6716587 (2004-04-01), Mosley
patent: 7186809 (2007-03-01), Pluenneke
patent: 7317090 (2008-01-01), Mosley et al.
patent: 2005/0255532 (2005-11-01), Ruben
patent: 2005/0282181 (2005-12-01), Yan
patent: 2007/0041976 (2007-02-01), Pluenneke
patent: 2007/0274996 (2007-11-01), Carter et al.
patent: 2009/0074793 (2009-03-01), Martin
patent: 2009/0098142 (2009-04-01), Kasaian et al.
patent: 0 604 693 (1994-07-01), None
patent: 0 367 566 (1997-05-01), None
patent: WO 01/92340 (2001-12-01), None
patent: WO 2005/047331 (2005-05-01), None
patent: WO 2005/085284 (2005-09-01), None
patent: WO 2006/072564 (2006-07-01), None
Zurawski et al., 1995, “The primary binding subunit of the human interleukin-4 receptor is also . . . ” J. Biol. Chem. 270:13869-13878 (Am. Society Biochem Mol. Biol, USA).
Holt et al., 2003, “Domain antibodies: Proteins for Therapy,” Trends Biotechnol. 21:484-490 (Cell Press, Cambridge, GB).
Davies et al., 1996, “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions . . . ” Immunotechnol. 2:169-179 (Elsevier, Netherlands).
Gavett et al., 1997, “Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge . . . ” Am J Physiol 272:L253-61 (American Physiological Society, USA).
Tomkinson et al., 2001, “A Murine IL-4 Receptor Antagonist That Inhibits IL-4- and IL-13-Induced Responses . . . ” J Immunol 166:5792-800 (American Assoc of Immunologists, USA).
Maliszewski et al., 1994, “In Vivo Biological Effects of Recombinant Soluble Interleukin-4 Receptor.” Proc Soc Exp Biol Med 206:233-7 (Blackwell Science, USA).
Sato et al., 1993, “Recombinant Soluble Murine IL-4 Receptor Can Inhibit or Enhance IgE Responses in Vivo.” J Immunol 150:2717-23 (American Association of Immunologists, USA).
Fairhurst Jeanette L.
Huang Tammy T.
Martin Joel H.
Papadopoulos Nicholas J.
Cottingham, Esq. Frank R.
Gregg, Esq. Valeta
Rawlings Stephen
Regeneron Pharmaceuticals Inc.
LandOfFree
High affinity human antibodies to human IL-4 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High affinity human antibodies to human IL-4 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High affinity human antibodies to human IL-4 receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252938